Drug intelligence / Profile preview

PLT012M

Development stage: Unknown
Lead developer: Pilatus Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PLT012M is a monoclonal antibody targeting CD36 (cluster of differentiation 36), developed by Pilatus Biosciences for the treatment of chronic liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH), advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). CD36 is a scavenger receptor that plays a critical role in lipid uptake and metabolism. By blocking CD36-mediated lipid uptake, PLT012M aims to reduce hepatic steatosis, inhibit the activation of inflammatory macrophages, and mitigate endothelial dysfunction and fibrogenic signaling in the liver. The drug is currently in Phase 1/2 development.

Other names: anti-CD36 monoclonal antibodyanti-CD-36 monoclonal antibodyanti-CD 36 monoclonal antibody

Targets

CD36 (CD36 antigen)

Beyond the preview

Go deeper on PLT012M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLT012M.

Explore the full profile